For Research Use Only. Not for Human Consumption.
Recorded market$87.08Recorded exact-size market estimate: 87.08 USD for one 10 mg container (8.708221 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$91.97Member price$82.774.9% lessMembers save $4.31 on this item vs. recorded market
Thymic peptide for immune-signaling research.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$8.28/mg4.9% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 05:18 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Pepta Labs Oct 11, 2026 UTC | One 10 mg container; 50.86 USD | $5.09/mg | powder; publicly listed ExactoneTA110mgdrypowdervial50.86USD; 3/5-vialpacksnotused; USonlydelivery. Price observation; no COA authentication is implied by inclusion. |
| BergdorfBio Oct 11, 2026 UTC | One 10 mg container; 114.99 USD | $11.50/mg | powder; publicly listed USD114.99TA110mg1pack(singlevial), lyophilizedpowder; multivialtiers excluded. Price observation; no COA authentication is implied by inclusion. |
| PeakForm Peptides Oct 11, 2026 UTC | One 10 mg container; 75.00 USD | $7.50/mg | powder; publicly listed ExactUSD75publisher10MG ProductOffer; expandedtablelyophilizedpowder3mLvial5|10mg. Default5mg40notused. Price observation; no COA authentication is implied by inclusion. |
| Peptara Labs Oct 11, 2026 UTC | One 10 mg container; 77.50 USD | $7.75/mg | powder; publicly listed Exactone10mglyophilizedTA1vial77.50USDpre-sale. Preorderdispatch28Oct2026, COApending. Price observation; no COA authentication is implied by inclusion. |
| Beyond Health Lab Oct 11, 2026 UTC | One 10 mg container; 1,800.00 MXN | $9.89/mg | powder; publicly listed Exact10mg lyophilized singlevial; automatic displayed sale1800MXN, regular2150MXN notused. Price observation; no COA authentication is implied by inclusion. |
| Pure Bio Labs Oct 11, 2026 UTC | One 10 mg container; 99.99 USD | $10.00/mg | powder; publicly listed Exactselected10mglyophpowder1PACK, USDprimaryOffer; two/threepacks excluded. Price observation; no COA authentication is implied by inclusion. |
| BioEdge Research Labs Oct 11, 2026 UTC | One 10 mg container; 88.00 USD | $8.80/mg | powder; in stock Explicit10mg fillwhite/offwhitelyophpowder, pressed1Vialq1, 88USDOffer currentautomaticsale98; stableopenpublicprice. BEC30coupon andbulkdiscountnotused. Price observation; no COA authentication is implied by inclusion. |
| Direct SARMS (United States) Oct 11, 2026 UTC | One 10 mg container; 70.31 USD | $7.03/mg | lyophilized powder; publicly listed Selected 10mg vial radio changes price from generic239.05 to70.31USD; explicit10mgvial·singlevial selected,qty1. Header explicitlyUSD; body lyophilizedpowder. Noentryaccount/professionalgate afterstableload. Largerpack andkit excluded. 1stOrdercoupon excluded. Price observation; no COA authentication is implied by inclusion. |
| Midshire Labs Oct 11, 2026 UTC | One 10 mg container; 35.00 GBP | $4.63/mg | lyophilized powder; publicly listed Open retailonevial GBP35 includingVAT qty1. Screenshot vial explicitly10MG; publisherWebPage description10mg andimagecaption10mg. Body says lyophilizedsolid sealed3mLvial. Noprofessional/accountentrygate afterstableload. FXECB9Oct2026 USDperGBP=1.1206/0.84763. OCTOBER5couponexcluded. Price observation; no COA authentication is implied by inclusion. |
| Core Peptides Oct 11, 2026 UTC | One 10 mg container; 149.00 USD | $14.90/mg | powder; in stock Publicexact10mgvariantProduct/OfferSKU P-THYMOSALFA1-10 USD149 exclVAT; UI10mgselected q1 butheroremains81–149range, exactmappedOfferused. Ownspec10mg/vial lyophpowder. Singlevialinferredq1/vialamount/noindicatedkit. Bulktiersnotused, noentrygate afterstablescreenshot. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Thymosin Alpha-1 – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/thymosin-alpha-1-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/thymosin-alpha-1-10-mg/
A thymic 28-amino-acid peptide used in laboratory research on innate and adaptive immune signaling.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Thymosin alpha-1 has been investigated in disease-specific clinical trials. Results differ across studies; a general immune-boosting claim obscures both the patient setting and the uncertainty.
Thymosin alpha-1 is distinct from thymosin beta-4, the TB-500 fragment and thymus-derived polypeptide extracts such as Thymalin.
A trial using a defined preparation in a particular infection cannot establish the effects of all thymic peptides or an uncharacterized vendor material.
The selected human trials provide mixed evidence. Two hepatitis-B trials reached different conclusions, while a severe-sepsis trial produced analysis-dependent mortality findings. These distinctions are more useful than combining all favorable observations into one efficacy grade.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
Double-blind placebo-controlled trial in 97 patients with chronic hepatitis B Reading scope: PubMed bibliographic record and abstract |
The prespecified complete-response comparison did not reach conventional statistical significance, and the authors did not confirm efficacy reported previously. | A numerically higher response is not equivalent to a conclusive treatment benefit. |
| Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial.
Randomized controlled trial in 98 patients with chronic hepatitis B Reading scope: PubMed bibliographic record and abstract |
The shorter treatment group had a more favorable later virological response than the untreated comparison group; results varied with timing and group. | The trial was not the same design as the placebo-controlled study, and findings cannot be combined without examining endpoints and follow-up. |
| The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.
Multicenter single-blind randomized severe-sepsis trial with 361 participants Reading scope: PubMed bibliographic record and abstract |
Mortality was numerically lower with adjunctive thymosin alpha-1; statistical results differed by analysis and the risk-ratio confidence interval included no difference. | This is not a definitive general survival claim and does not apply to healthy people seeking immune enhancement. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
The disease, background treatment, endpoint definition and time of measurement can explain why trials appear to disagree. A later response analysis is not the same as success on the original primary endpoint.
Immune markers do not specify whether an intervention helps a particular patient. The useful question is whether a well-controlled trial improves a meaningful clinical outcome with acceptable harms.
No serious drug-related event in a particular trial does not establish safety across diseases or routes. FDA also flags route-dependent immunogenicity and characterization concerns for proposed compounded thymosin-alpha-1 products.
Read disease-specific exposure and background therapy together. A repeated dose used in a hepatitis trial is not a universal immune-support schedule, and ICU protocols cannot be detached from supervised care.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Require explicit thymosin alpha-1 identity rather than the generic word thymosin. Do not accept analysis of a beta peptide or thymus extract as documentation of the alpha-1 preparation.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. One reported a favorable later response, while the multicenter blinded placebo-controlled study did not confirm the earlier efficacy findings.
No. It studied critically ill patients receiving conventional medical care, not prevention or wellness use in healthy adults.
This companion to the Thymosin alpha-1 research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Read disease-specific exposure and background therapy together. A repeated dose used in a hepatitis trial is not a universal immune-support schedule, and ICU protocols cannot be detached from supervised care.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.